ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Pretty Quiet / Gov Clinical Trials

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von May 17, 2023 7:24am

120 Views

Post# 35451830

RE:Pretty Quiet / Gov Clinical Trials

FarmerBetty wrote: Tried to find Promis listed under US gov clinical trials where the alzheimers trials are listed as active, recruiting, etc. Might mean nothing but would of thought with all the delays that if they were serious about going into the clinic the company would have the foot on the pedal.

Before PMN initiates Phase 1a they need the funding in place.

"Cash and cash equivalents were $3.3 million as of March 31, 2023,"

G1945V

<< Previous

Bullboard Posts

Next >>

Consumer advocacy law firm investigates Microsoft over X-Box data concerns